News | December 07, 2025
Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Innovent will supply sintilimab for the collaborated clinical trial
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
